According to existing guidelines, SC is appropriate in patients with a single involved colonic segment. However, data on SC and TC in patients with CD and multiple involved colonic segments is limited and of low quality, according to Dr Gianluca Pellino (University of Campania Luigi Vanvitelli, Italy) [1]. Therefore, the current SCOTCH trial aimed to compare the surgical recurrence rates, perioperative complications, and stoma formation rates of SC and TC in participants with primary, colonic CD (n=687). SC was defined as the resection of 1–3 segments, whereas TC involved the resection of >3 segments.
The surgical recurrence rate was significantly higher in participants who underwent TC compared with those who underwent SC (P=0.006). This result did not change with the number of segments involved (P=0.2). Furthermore, participants who underwent TC had an increased risk of a temporal stoma (31.6% vs 21.4%; P=0.0007) or a permanent stoma (39.3% vs 8%; P<0.0001). In addition, re-admissions occurred more frequently in participants who underwent TC (6% vs 2.1%; P=0.02).
Postoperative treatment with biologics reduced the risk of recurrence (25% vs 51%; P<0.001) in patients with 1–3 segments involved. Perioperative complications were numerically more frequently reported in the TC arm than in the SC arm but did not differ significantly (P=0.07). The rate of major complications was similar for the 2 groups (10.2% and 9.7%; P=0.9). Interestingly, not receiving biologic therapy was a significant predictor of recurrence (HR 5.4; P<0.0001). In addition, perianal CD (HR 1.9) and CD diagnosis before 18 years of age (HR 2.7) were predictive of recurrence.
Dr Pellino argued that these findings may be practice changing. “SC may be discussed in patients with limited colonic disease, younger patients, and those who do not display inflammatory extensive colitis, but rather have penetrating or structuring disease. The results clearly show the importance of biologic therapies in the setting of colectomy. To conclude, future studies should thoroughly investigate the application of SC in ulcerative colitis as well.”
- Pellino G, et al. Segmental vs Total Colectomy for Crohn’s disease of the colon in the biologic era. Results from the SCOTCH international, multicentric study. OP12, ECCO 2022, 16–19 February.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative Next Article
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy »
« Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative Next Article
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy »
Table of Contents: ECCO 2022
Featured articles
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Novel Treatment Modalities
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Guselkumab plus golimumab promising combination for ulcerative colitis
Combined endpoint may support personalised medicine in ulcerative colitis
Filgotinib seems promising for perianal fistulising Crohn’s disease
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Upadacitinib counters extraintestinal manifestations in ulcerative colitis
Deucravacitinib does not meet primary endpoint for ulcerative colitis
Head-to-Head Comparisons
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis
Short-Term and Long-Term Treatment Results
Ozanimod treatment shows maintained response in ulcerative colitis
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
Vedolizumab first approved therapy for chronic pouchitis
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Specific Therapeutic Strategies
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative
Similar results for different corticosteroid tapering protocols in UC
Miscellaneous Topics
Lessons from the COVID-19 pandemic for IBD management
AI model distinguishes between histologic activity and remission in ulcerative colitis
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools
Related Articles
November 28, 2024
TL1A inhibitor tulisokibart shows potential in UC
March 23, 2022
Pfizer’s bowel disease drug succeeds in late-stage study
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com